PRESS RELEASE

GLOBAL CANCER TECHNOLOGY

For Immediate Release

Contact: info@globalcancertechnology.com

GLOBAL CANCER TECHNOLOGY PATENTS ISSUED IN JAPAN

BOLSTERS MARKET OPPORTUNITY FOR PROPRIETARY PI3K INHIBITOR DRUGS

San Diego, CA, January 10th, 2024 – Global Cancer Technology, Inc. announced today that two of its drug compounds GCT-007, a potent small molecule PI3K inhibitor, and GCT-008, an inhibitor of vacuolar protein sorting 34 (VPS34), were granted patent protection status by the Japan Patent Office, which issued Patent Application No. 2020-555504 and Patent Application No. 2020-555501, respectively. Global Cancer Technology has exclusive worldwide licensing rights for both drugs from Neuropore Therapies, Inc.

The Company has largely focused its preclinical research programs on the treatment of glioblastoma and certain forms of treatment-resistant breast cancer. Both are areas of significant unmet medical need and cancers where the PI3K pathway can play an instrumental role in effecting treatment. Presently there are no PI3K inhibitors approved for the treatment of glioblastoma in the US or Japan.

“We are delighted to add this patent protection issued by the Japan Patent Office to our existing protection in the US”, said John Clark, the CEO of Global Cancer Technology. Mr. Clark further stated, “These newly issued patents from Japan symbolize our commitment to the worldwide IP protection of our assets, and we will continue to expand our worldwide IP protection for both GCT-007 & GCT-008”.

The market for the treatment of glioblastoma in Japan was estimated at around $0.16 billion in 2022 and is projected to reach $0.32 billion by 2030, exhibiting a CAGR of 9.4%, making it an attractive market to have IP protection.

---

*Global Cancer Technology is a pre-clinical non-revenue biopharma company that is currently raising investment capital to enter a Phase 1 clinical trial {**globalcancertechnology.com**}. Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent shareholder letter. There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized.*